Core Viewpoint - The article emphasizes the importance of dividend stocks as a reliable investment option, particularly during varying market conditions, highlighting three companies known as Dividend Kings that are recommended for long-term investment. Group 1: Dividend Kings Overview - Dividend Kings are companies that have increased their dividends for at least 50 consecutive years, indicating a strong commitment to returning value to shareholders [3]. - These companies provide passive income and can offer stability during market downturns while also benefiting from market upswings [2]. Group 2: Abbott Laboratories - Abbott Laboratories has a dividend of $2.52, yielding 2.4%, which is higher than the S&P 500's 1.1% yield [4]. - The company has a diversified healthcare business with four units: medical devices, diagnostics, nutrition, and established pharmaceuticals, providing security against downturns in any single unit [6]. Group 3: Target - Target has faced challenges recently, including a shift in consumer behavior and theft, but is implementing strategies to recover, such as creating an enterprise acceleration office [7][8]. - The company offers a dividend of $4.56, yielding 4.5%, which can provide passive income while the stock potentially rebounds [10]. Group 4: Johnson & Johnson - Johnson & Johnson spun off its consumer health business to focus on higher-growth areas, resulting in a 6% sales increase to over $94 billion last year and an 8% rise in adjusted diluted earnings per share [11][12]. - The company pays a dividend of $5.20, yielding 2.3%, making it a solid choice for passive income [14].

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medical device mergers and acquisitions accelerated in the second half of 2025, propelled by several large deal announcements, according to a report released this month by Bain & Company. Medtech M&A brought in a total value of about $80 billion through Nov. 30, 2025, surpassing the previous three years. Much of the activity took place in the second half of the ye ...

Abbott Laboratories (ABT) shares snapped six straight sessions of losses, as the stock closed 1.2% higher at $108.77 on Monday. The MedTech giant started its downward trend on Jan. 15. The stock has lost over 13% in the preceding six sessions. ...

Core Insights - Abbott Laboratories is a global healthcare company with a diverse product range, facing recent stock challenges but remaining a strong industry player [1] Stock Performance - The current stock price of Abbott Laboratories (ABT) is $107.42, reflecting a decrease of approximately -1.10% [4] - Over the past year, ABT has reached a high of $141.23 and a low of $105.78, with a market capitalization of approximately $186.96 billion [4] - The trading volume for ABT on the NYSE is 21,703,521 shares [4] Executive Actions - Ford Robert B, Chairman and CEO, purchased 18,800 shares at approximately $107.13 each, increasing his total ownership to 216,203 shares, signaling confidence in the company's future [2][6] Company Ratings and Forecasts - Abbott Laboratories is rated as a 'Buy' despite recent stock price declines, primarily due to weaknesses in its Nutrition segment and a decrease in COVID-19 diagnostics [3][6] - The Medical Devices segment, particularly Continuous Glucose Monitoring (CGM) products, continues to show strong double-digit growth, counterbalancing challenges in the Nutrition sector [3] - The company forecasts a 7% increase in sales and a 10% growth in earnings per share (EPS) for 2025, supported by ongoing innovation and a return to normalcy in the Nutrition segment [5][6]

Group 1 - iREIT+HOYA Capital focuses on income-producing asset classes that provide sustainable portfolio income, diversification, and inflation hedging [1] - The investment group targets high-yield, dividend growth opportunities, offering portfolios with dividend yields up to 10% [2] - The service provides research on various investment vehicles including REITs, ETFs, closed-end funds, preferreds, and dividend champions [2] Group 2 - The investment approach is defensive in nature, aimed at medium- to long-term horizons [2] - The group emphasizes dependable monthly income for investors [2]

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.I am Gen Alpha. I have more than 14 years of investment experience, and an MBA in Finance. I focus on stocks that are more defensive in nature, with a medium ...

Core Viewpoint - Abbott Laboratories (ABT), known as a Dividend King, experienced a decline in stock price following a mixed Q4 earnings report, indicating resilience but also facing headwinds in certain segments [1] Financial Performance - The Q4 earnings report was mixed, suggesting that while the company shows resilience, there are negative impacts from challenges in some segments [1] Market Reaction - The stock price drop reflects investor sentiment in response to the earnings report, highlighting the market's reaction to the company's performance [1]

As filed with the Securities and Exchange Commission on January 23, 2026. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MiniMed Group, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 33-3985981 (I.R.S. Employer Identification Number) 18000 Devonshire St. N ...

Core Insights - Zacks Premium offers tools for investors to enhance their stock market engagement and confidence through various resources like daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores provide a rating system for stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [2] - Stocks are rated from A to F, with A indicating the highest potential for outperforming the market [3] Value Score - The Value Score identifies attractive stocks using financial ratios such as P/E, PEG, and Price/Sales, appealing to value investors seeking undervalued opportunities [3] Growth Score - The Growth Score focuses on a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth [4] Momentum Score - The Momentum Score helps investors capitalize on price trends, utilizing metrics like weekly price changes and monthly earnings estimate changes to identify optimal entry points [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator that highlights stocks with strong value, growth potential, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist in portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.9% since 1988, significantly outperforming the S&P 500 [7] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down choices [8] Stock to Watch: Abbott (ABT) - Abbott, rated 2 (Buy) on the Zacks Rank, has a VGM Score of B and a Value Style Score of B, with a forward P/E ratio of 19.16, indicating attractive valuation [11] - Recent upward revision of earnings estimates for fiscal 2026 has increased the Zacks Consensus Estimate to $5.67 per share, with an average earnings surprise of +0.7% [12]

Core Insights - Abbott Laboratories reported Q4 2025 sales of $11.46 billion, a 4.4% increase year-over-year, but fell short of analyst projections by approximately 3% [2] - Adjusted EPS for the quarter was $1.50, meeting expectations, while total annual adjusted EPS reached $5.15, indicating a 10% growth [2] Financial Performance - Organic sales growth decreased to 3% during the quarter due to reduced demand in some areas [4] - Adjusted gross margin increased by 20 basis points to 57.1%, and operating margin expanded by 150 basis points to 25.8%, reflecting effective cost management [4] - Guidance for 2026 projects organic sales growth of 6.5%-7.5% and an adjusted EPS around $5.68 at the midpoint, aligning with consensus expectations [6] Valuation Dynamics - Abbott is currently priced at around $109 per share, trading at 21 times its trailing adjusted EPS of $5.15, down from a three-year average P/E of 24 times [6][7] - The forward P/E based on guidance is 19 times, indicating potential stability, but slowdowns in Nutrition and uncertainties regarding acquisitions limit optimism [7] Segment Performance - Medical Devices segment showed strong demand, particularly in structural heart and neuromodulation, with Freestyle Libre contributing significantly to organic growth [10] - Diagnostics revenue is normalizing post-COVID, with the Exact Sciences acquisition valued at up to $23 billion expected to enhance this sector [10] - Nutrition sales declined due to market dynamics, raising concerns about future growth in this segment [10] Future Catalysts and Risks - Potential upside for Abbott depends on realizing synergies from Exact Sciences, stabilization in Nutrition, and successful execution in high-growth devices [8] - Downside risks include persistent weakness in Nutrition, regulatory challenges with the Exact Sciences acquisition, and overall caution in medtech spending [9]